ILC Therapeutics is a specialist UK-based developer of hybrid interferons, a new engineered drug class with improved therapeutic profiles, enabling broad applications across multiple indications. Hybrid interferons combine favourable attributes of specific natural interferon sub-types to produce novel drug candidates designed to deliver reduced toxicity and improved efficacy. ILC Therapeutic’s platform approach has produced two first-in-class lead candidates, Alfacyte™ and Dermacyte™ focused on antiviral and dermatological indications respectively, which are progressing towards the clinic.